OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kim on Clinical Trial Eligibility Criteria in Lung Cancer

October 25th 2019

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.

Dr. Bryce on Treatment Selection in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Smith on Frontline Treatment Considerations in CLL

October 24th 2019

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Dr. Patel on Treatment Considerations in Advanced Squamous NSCLC

October 24th 2019

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria

October 24th 2019

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Dr. Kasi on the Prognostic Value of ctDNA in CRC

October 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Dr. Molena on Determining Surgical Resection Eligibility in NSCLC

October 24th 2019

Daniela Molena, MD, discusses factors that determine if a patient with non–small cell lung cancer is eligible for surgical resection.

Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

October 24th 2019

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate Cancer

October 24th 2019

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Dr. Shah on the Trastuzumab Biosimilar in Gastric Cancer

October 24th 2019

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. George on the Changing Treatment Landscape in Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

October 23rd 2019

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

Dr. Akerley on MET Biomarker in Lung Cancer

October 23rd 2019

Wallace L. Akerley, MD, discusses using MET as a biomarker in lung cancer.

Dr. Perl on Challenges of Implementing Immunotherapy in AML

October 23rd 2019

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.

Dr. Mahoney on Potential of VISTA-Targeting Therapy in RCC

October 23rd 2019

Kathleen Mahoney, MD, PhD, discusses the potential of targeting V-domain immunoglobulin containing suppressor of T-cell activation in renal cell carcinoma.

Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL

October 23rd 2019

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Preeshagul on Education for Biosimilars in Oncology

October 22nd 2019

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.

Dr. Frey on Measuring MRD Throughout Treatment for ALL

October 22nd 2019

Noelle Frey, MD, MSCE, discusses measuring minimal residual disease throughout treatment for patients with acute lymphocytic leukemia.

Dr. Offin on Potential Implications of Introducing Biosimilars Into Oncology

October 22nd 2019

Michael D. Offin, MD, discusses the potential implications of introducing biosimilars into the field of oncology.